The FDA recently approved new language for the label of J&J's 9-year-old schizophrenia treatment, Invega Sustenna, stating that the drug can delay the arrest or incarceration of patients taking it. Now some mental health experts are questioning whether allowing J&J to market a drug for that purpose is really a good idea.Original Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.